Europe - BIT:1ROG - CH0012032048 - Common Stock
The current stock price of 1ROG.MI is 314 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SNW.DE | SANOFI | 11.8 | 218.39B | ||
| SAN.PA | SANOFI | 11.79 | 218.24B | ||
| 1SAN.MI | SANOFI | 11.86 | 219.58B | ||
| MRK.DE | MERCK KGAA | 17.01 | 51.11B | ||
| 1MRK.MI | MERCK KGAA | 13.27 | 49.11B | ||
| UCB.BR | UCB SA | 35.34 | 44.13B | ||
| 1BAYN.MI | BAYER AG-REG | 5.78 | 27.92B | ||
| BAYN.DE | BAYER AG-REG | 5.77 | 27.91B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 26.8 | 11.04B | ||
| IPN.PA | IPSEN | 12.81 | 11.03B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.63 | 8.95B | ||
| VIRP.PA | VIRBAC SA | 20.33 | 2.96B |
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
ROCHE HOLDING AG-GENUSSCHEIN
Grenzacherstrasse 124
Basel BASEL-STADT CH
Employees: 103249
Phone: 41616881111
Roche Holding AG is a research healthcare company. The company is headquartered in Basel, Basel-Stadt and currently employs 103,249 full-time employees. The company went IPO on 2001-05-04. The firm's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The firm develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The firm offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
The current stock price of 1ROG.MI is 314 EUR. The price increased by 9.03% in the last trading session.
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a dividend yield of 3.35%. The yearly dividend amount is currently 11.
1ROG.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1ROG.MI.
ROCHE HOLDING AG-GENUSSCHEIN (1ROG.MI) has a market capitalization of 254.10B EUR. This makes 1ROG.MI a Mega Cap stock.
ChartMill assigns a technical rating of 3 / 10 to 1ROG.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1ROG.MI. While 1ROG.MI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months 1ROG.MI reported a non-GAAP Earnings per Share(EPS) of 21.42. The EPS increased by 5.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.31% | ||
| ROA | 9.95% | ||
| ROE | 32.88% | ||
| Debt/Equity | 1.06 |
For the next year, analysts expect an EPS growth of 5.57% and a revenue growth 2.13% for 1ROG.MI